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To the Editor:
Hypertension is a strong and independent risk factor for
cardiovascular morbidity and mortality. Treatment effec-
tively prevents major complications such as stroke and
myocardial infarction. Until recently worldwide practice
was to prioritize the control of diastolic blood pressure
(BP), as most interventional trials showing the benefit of
drug therapy have taken diastolic BP as both an inclusion
criterion and a target. However, the epidemiologic evi-
dence indicates that systolic BP is the better predictor of
cardiovascular morbidity and mortality.1 Systolic control
also provides significant protection against cardiovascular
complications.2 Large trials in elderly patients with iso-
lated systolic hypertension prompted the formulation of
international guidelines recommending the normalization
of both systolic and diastolic BP,3,4 currently to less than
140/90 mm Hg in all hypertensive patients, and lower still
in the presence of concomitant diabetes or chronic renal
disease. Notably, the excess risk of cardiovascular mortal-
ity found in treated hypertensive as compared with un-
treated normotensive individuals of the same age appears
to be due mainly to persistently high systolic BP levels
under treatment.5
Because there is more success in achieving diastolic
than systolic control at both primary care level6 and in
interventional trials,7 it is reasonable to assume that most
patients in whom it has been possible to lower systolic BP
to less than 140 mm Hg will have a diastolic BP less than
90 mm Hg. To verify this assumption we analyzed the data
from the STRAtegies of Treatment in Hypertension: Eval-
uation (STRATHE) community study comparing different
treatment strategies for uncomplicated essential hyperten-
sion.8
The STRATHE study was performed in France by 193
community physicians in 533 patients with a mean sitting
systolic BP 160 mm Hg or mean diastolic BP 95 mm
Hg after a 4-week single-blind placebo run-in. Of them,
470 had stage 2 hypertension (systolic BP 160 mm Hg
or diastolic BP 100 mm Hg). The present analysis fo-
cuses on these patients as they met the criteria to receive
a fixed dose combination as initial treatment in agreement
with both European Society of Hypertension/European
Society of Cardiology (ESH/ESC) and Joint National
Committee (JNC) 7 guidelines.3,4 After randomization to a
fixed low-dose combination (perindopril/indapamide, 2
mg/0.625 mg, increased first to 3 mg/0.937 mg and later,
if required, to 4 mg/1.25 mg [n  162]), sequential mono-
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Published by Elsevier Inc.therapy (atenolol 50 mg, followed by losartan 50 mg, and
amlodipine 5 mg as needed [n  151]), or stepped care
(valsartan 40 mg, increased if necessary to 80 mg, then to
valsartan 80 mg plus hydrochlorothiazide 12.5 mg if the
target pressure was still not achieved [n  157]), patients
were treated double-blind for 9 months to a target BP
140/90 mm Hg. The three groups did not differ signifi-
cantly in baseline age, body mass index, BP, and pulse
pressure. All study tablets were encapsulated to conceal
their identity and were taken once daily. The final visit
took place at the end of month 9, or end of month 6 if the
target BP had been reached. The primary end point was the
BP normalization rate at final visit. Results were analyzed
using the 2 test.
FIG. 1. Percentage of patients with stage 2 hypertension achieving
the target blood pressure (BP) of 140/90 mm Hg (A) at final visit,
a systolic BP (SBP)140 mmHg while retaining a diastolic BP (DBP)
90 mm Hg (B), and a DBP 90 mm Hg while retaining an SBP
140 mm Hg (C).
0895-7061/06/$32.00
986 AJH–September 2006–VOL. 19, NO. 9CORRESPONDENCEIntention-to-treat analysis showed a significantly higher
normalization rate with the low-dose combination (64.2%)
than with sequential monotherapy (50.3%, P  .004) or
stepped care (48.4%, P .01). Only 3.4% of patients with a
systolic BP 140 mm Hg retained a diastolic BP 90 mm
Hg, whereas 16.6% of those with a diastolic BP90 mm Hg
retained a systolic BP 140 mm Hg (Fig. 1).
It has been difficult to determine whether the greater
success reported in the control of diastolic versus systolic
BP is grounded in pathophysiology or investigator bias. It
is, for example, impossible to be sure to what extent
physicians participating in interventional trials, including
at the primary care level, endorse current recommenda-
tions to achieve tight systolic control. The fact that most
interventional trials aimed to normalize diastolic but not
necessarily systolic BP complicates interpretation of the
apparently differing impact of antihypertensive treatment
on each parameter.7
The STRATHE study gave equal priority to diastolic
and systolic control. The results confirm the genuinely
greater difficulty of achieving systolic control.8 They re-
flect everyday practice in that they were obtained using
current guidelines and standard treatment strategies and
durations. The superior control achieved by the fixed low-
dose perindopril/indapamide combination was due to a
greater effect on systolic BP.
The key message of this analysis is that once systolic BP
is brought to less than 140 mm Hg, diastolic BP is almost
invariably90 mm Hg, suggesting that the systolic/diastolic
BP normalization rate would have been the same if the
decision to change or intensify treatment had been based on
systolic BP alone, instead of on both pressures as was the
case. Can we now afford to abandon the measurement of
diastolic BP as proposed in 1999 by Sever9? A confident
positive answer must await the outcome of dedicated inter-
ventional trials. Evidence, however, already exists indicating
that a high diastolic BP is not associated with an adverse
prognosis if systolic BP is 140 mm Hg.10
BERNARD WAEBER
Division of Clinical Pathophysiology
University Hospital
Lausanne, SwitzerlandJEAN-JACQUES MOURAD
Hypertension unit
Avicenne hospital—AP-HP and Paris XIII University
(EA 3412)
Bobigny, France
doi:10.1016/j.amjhyper.2006.03.012
Address correspondence and reprint requests to Professor Bernard Wae-
ber, Division of Clinical Pathophysiology, MP 14, University Hospital,
CH-1011 Lausanne, Switzerland; e-mail: Bernard.Waeber@chuv.ch
References
1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R: Age-
specific relevance of usual blood pressure to vascular mortality: a
meta-analysis of individual data for one million adults in 61 pro-
spective studies. Lancet 2002;360:1903–1913.
2. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel
JP, Coope J, Ekbom T, Gueyffier F, Liu L, Kerlikowske K, Pocock
S, Fagard RH: Risks of untreated and treated isolated systolic
hypertension in the elderly: meta-analysis of outcome trials. Lancet
2000;355:865–872.
3. 2003 European Society of Hypertension–European Society of Car-
diology: Guidelines for the management of arterial hypertension.
J Hypertens 2003;21:1011–1053.
4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA,
Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella
EJ: Seventh report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure. Hy-
pertension 2003;42:1206–1252.
5. Benetos A, Thomas F, Bean KE, Guize L: Why cardiovascular
mortality is higher in treated hypertensives versus subjects of the
same age, in the general population. J Hypertens 2003;21:1635–
1640.
6. Swales JD: Current clinical practice in hypertension: the EISBERG
(Evaluation and Interventions for Systolic Blood pressure Eleva-
tion-Regional and Global) project. Am Heart J 1999;138:231–237.
7. Mancia G, Seravalle G, Grassi G: Systolic blood pressure: an
underestimated cardiovascular risk factor. J Hypertens 2002;
20(Suppl 5):21–27.
8. Mourad JJ, Waeber B, Zannad F, Laville M, Duru G, Andrejak M:
Comparison of different therapeutic strategies in hypertension: a
low-dose combination of perindopril/indapamide versus a sequen-
tial monotherapy or a stepped-care approach. J Hypertens 2004;22:
2379–2386.
9. Sever PS: Simple blood pressure guidelines for primary health care.
J Hum Hypertens 1999;13:725–727.
10. Pickering TG: Isolated diastolic hypertension. J Clin Hypertens
2003;5:411–413.
